Soligenix Receives Hong Kong Patent for Improved Production of Synthetic HypericinPRNewsWire • 10/22/24
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer ConferencePRNewsWire • 10/07/24
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 09/20/24
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024PRNewsWire • 09/16/24
Soligenix Receives European Patent for Improved Production of Synthetic HypericinPRNewsWire • 09/03/24
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 08/16/24
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial ResultsPRNewsWire • 08/09/24
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study ResultsGlobeNewsWire • 07/15/24
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaPRNewsWire • 07/09/24
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 06/25/24
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe ConferencePRNewsWire • 06/14/24
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 06/07/24
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication TrialMCAP MediaWire • 06/05/24
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingPRNewsWire • 05/24/24